0000950170-22-013212.txt : 20220727 0000950170-22-013212.hdr.sgml : 20220727 20220727161140 ACCESSION NUMBER: 0000950170-22-013212 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220726 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220727 DATE AS OF CHANGE: 20220727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Terns Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001831363 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39926 FILM NUMBER: 221111139 BUSINESS ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-525-5535 EXT.101 MAIL ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 8-K 1 tern-20220726.htm 8-K 8-K
0001831363false00018313632022-07-262022-07-26

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 26, 2022

 

 

Terns Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39926

98-1448275

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1065 East Hillsdale Blvd.

Suite 100

 

Foster City, California

 

94404

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 525-5535

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TERN

 

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Radhika Tripuraneni to the Board of Directors

 

On July 26, 2022, the Board of Directors (the “Board”) of Terns Pharmaceuticals, Inc. (the “Company”) appointed Radhika Tripuraneni, M.D., M.P.H. to serve as a Class II director until her successor is duly elected and qualified or until her earlier death, resignation or removal. Dr. Tripuraneni was also appointed to the serve as a member of the Audit Committee of the Board.

 

There is no arrangement or understanding between Dr. Tripuraneni and any other person pursuant to which she was appointed as a director of the Company, and there are no family relationships between Dr. Tripuraneni and any of the Company’s directors or executive officers. There are no transactions to which the Company is a party and in which Dr. Tripuraneni has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.

 

Dr. Tripuraneni is eligible to receive cash compensation and equity awards pursuant to the amended and restated compensation program for the Company’s non-employee directors, which is described in more detail in the Company’s proxy statement filed with the Securities and Exchange Commission on April 29, 2022.

Item 7.01 Regulation FD Disclosure.

On July 27, 2022, the Company announced the appointment of Dr. Tripuraneni to the Board. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.

 

 

Description

 

 

 

99.1

 

Press Release issued by Terns Pharmaceuticals, Inc. on July 27, 2022.

104

 

Cover Page Interactive Data File, formatted in inline XBRL.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

TERNS PHARMACEUTICALS, INC.

 

 

 

 

Date:

July 27, 2022

By:

/s/ Bryan Yoon

 

 

 

Bryan Yoon
Chief Operating Officer & General Counsel

 

 EX-99.1 2 tern-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img52906712_0.jpg 

Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

 

FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) – Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Corporation plc and brings to the Terns Board of Directors more than 15 years of experience in drug development.

“Terns’ approach of discovering and developing next-generation small molecules for clinically de-risked targets in indications with significant unmet need is an exciting strategy,” said Dr. Tripuraneni. “I am thrilled to join this accomplished team and look forward to working with the board and the management team to advance three clinically validated mechanisms in three indications with large, unmet needs towards three important clinical readouts across NASH, oncology and obesity.”

“Dr. Tripuraneni has a breadth of scientific, medical and drug development expertise and I am pleased to have her join our board of directors where she will provide valuable support to our mission,” said Sen Sundaram, Chief Executive Officer of Terns. “Her strategic and operational experience in bringing important treatments to patients positions her well to guide Terns towards generating meaningful clinical data across several indications in the coming years.”

Dr. Tripuraneni has served as Prothena’s Chief Development Officer since 2018 and is a seasoned biotech executive. Prior to joining Prothena, Dr. Tripuraneni was Vice President, Medical Affairs and Chief of Staff to the Chief Medical Officer of MyoKardia Inc. She was Vice President, Medical Affairs at Synageva BioPharma Corp. and then Alexion Pharmaceuticals Inc., which acquired Synageva. Earlier in her career, Dr. Tripuraneni held various medical director and business development positions at Gilead Sciences, Inc. and Genzyme Corporation, and worked at Summer Street Research Partners, a healthcare equity research firm.

Dr. Tripuraneni earned her Bachelor’s degrees in business administration and liberal arts and her M.D. from the University of Missouri, and her Master’s in Public Health from Harvard University. She did her clinical training in general surgery at Harvard - Beth Israel Deaconess Medical Center.

About Terns Pharmaceuticals

 

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as NASH, obesity and cancer. Terns’ pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

 

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s expectations of timing and potential results of the Company’s clinical trials and other development activities; the potential indications to be targeted by the Company with its single-agent and combination therapy candidates; the therapeutic potential of the Company’s single-agent and combination therapy candidates; the potential for the mechanisms of action of the Company’s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company’s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company’s clinical trials; the Company’s clinical development plans and activities; the Company’s expectations regarding the profile of its product candidates, including tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; and the Company’s plans for and ability to continue to execute on its current clinical strategy. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. In particular, the impact of the COVID-19 pandemic on the Company’s ability to progress with its research, development, manufacturing and regulatory efforts, including the Company’s clinical trials for its product candidates, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the period ended March 31, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

 

 

 

Contacts for Terns

 

Investors

Justin Ng

investors@ternspharma.com

 

Media

Jenna Urban

Berry & Company Public Relations

media@ternspharma.com

 

 GRAPHIC 3 img52906712_0.jpg GRAPHIC begin 644 img52906712_0.jpg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end EX-101.LAB 4 tern-20220726_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 5 tern-20220726_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 6 tern-20220726.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information
Jul. 26, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 26, 2022
Entity Registrant Name Terns Pharmaceuticals, Inc.
Entity Central Index Key 0001831363
Entity Emerging Growth Company true
Entity File Number 001-39926
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 98-1448275
Entity Address, Address Line One 1065 East Hillsdale Blvd.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code 650
Local Phone Number 525-5535
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TERN
Security Exchange Name NASDAQ
XML 8 tern-20220726_htm.xml IDEA: XBRL DOCUMENT 0001831363 2022-07-26 2022-07-26 0001831363 false 8-K 2022-07-26 Terns Pharmaceuticals, Inc. DE 001-39926 98-1448275 1065 East Hillsdale Blvd. Suite 100 Foster City CA 94404 650 525-5535 N/A false false false false Common Stock, $0.0001 par value per share TERN NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tern-20220726.htm tern-20220726.xsd tern-20220726_lab.xml tern-20220726_pre.xml tern-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tern-20220726.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tern-20220726.htm" ] }, "labelLink": { "local": [ "tern-20220726_lab.xml" ] }, "presentationLink": { "local": [ "tern-20220726_pre.xml" ] }, "schema": { "local": [ "tern-20220726.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tern", "nsuri": "http://www.ternspharma.com/20220726", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tern-20220726.htm", "contextRef": "C_6f933c28-440d-4c65-8ed7-ac023b9a318e", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tern-20220726.htm", "contextRef": "C_6f933c28-440d-4c65-8ed7-ac023b9a318e", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ternspharma.com/20220726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0000950170-22-013212-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-013212-xbrl.zip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

5DJ$7GLID%FJLC )B$[CF06Z2>DAPWV@W+H M/K,M71AK>*I!:I@[92Z(M0)]^U15ORU*U4\[$WY!T9F 0,T90G]3L$5")T J&P3N3A-@[+M2V[)+/O)7^;&X@;8GG/Q(*= M)R(@5!\AYP4F[9)5,C4%D)CZ.^#*#*(UQS%R),X6]82C!5 6')ZD464F$O0+!'9FD79";1#D#<:0@^[FS4A5@3PD[T1HCM3SB [5_ MBDN\^S.NZWGT>#A!<;#]9.8CLNU'=W[X<<#K7;CH58=^G']=FP.[MC+>.) ; MBM4CD5K7BG83?)H63<:G&TV/;\,Z5G(::Z8HD%S[15C!FV9IS2/9\%$24MR7J.I1_4VIB@;Q/@D'N8,7QO I+LIPSZ>U-_G./QYW M[R3?H49"S9F&52%DTDN48"XV$09%BSW784_(R_/PV"'=T@A=GL;&%W.U^:QQ M2;^A&A\C:5DV4JF_T!YJMN>AE%C1K[G*0LF(Y,%JK[%QA9Q#JV4RXV<&R\1R MN95Q6>>1#G53WQZ@DG!=QDY2;LZ9C%+^?U#7"@Z46T'BL[_%OTI0\=%0Q74^M-"#1"M2#*EA::]7#/,&)[S%O9FOVQ5;S7%4FS>MLE[323,1$; YY?-N3U+GJRJ'MMS M[0S:+LW5L^2Z/OBTB#DT9Y7D#7]"CP#$2R9;!=ZRG=;-VD[$1_A\4A([=U3D=TO+$0GKM-TWG+L1HN\ M\0UJJ!QN7*6:ZU@8)]12[;NNY>6Z1XRYR(()&?87P$01([CV@2/@T(]D1RI8 M:82F"QM89:_[3-8-**/^LK1GR@M$S+F?H48DS2Z-1D-$'.%,">>B"CD1"]/0 MW@KN-NA\<54D(QI5%M0>&LRQNHY11^IR,T))2$UU#1E;WCG7E%N>3U"$P_4V M7W L+NMBJ[2(L6UOFB+;?(SZ'BG(EN?;9"B'H+9UWK 1F\^G1A:;3S5E$UN4 M*>66D-\!8/,5063+T[;%HK;,T)' EE>63H*WK,$I=;;EZ6R[00.G;\E<=+%E MTCD)Z9XNH[U#\E!(2P GIPWQ?"8]([O5-"8:QL;XH:*; 3A5>S[?.1XL3NX4 M0FD%-^<>=H@F2&\(U$QV08% B-PI[\%]*-[T4@AJ5$Y"4YY%7.$U?+6C6*SS M73]*)"+"B^C"6 7G;-?0TD1HFW$FN66='1&%I09S:2]:1W+@" 0),'_J68>M MS-7+S_KLU75$(O^M3O>&3*DN$S"EF",Y7VBS04H"9J(PG MXEZ(IH8)KTJTW3H\5DS%&XAI^U_0-8F&G8PB$UU<"A9=U9C-R20"JFR<"M?V M4M_TLMH8$S7HB:7+JU,TCI28\YP*6=IYB@[%8CT%:E5RSL#8Q/;=U21$RS:( M)QQ!DC;K3KJ\+%E1;BV'VLQZ6ESV'*?KF/:NA*TEX2U&>P>2'LJWS]?2+08) M/ L!H8%3)-%>D-9I]>K'YX\'HST,0TE:(HTQEZ1RO>2BRT.[O#XJGO2U3BB" M-I0@--T]-X1\J(+D82%4#FCYC1ST=\L4RG8NR^7X^DVF:D7D5D6S]G3J,=L, MWD,@C\B+Q]0$_TE'?!$!\-N<0G:JJ-''*0ZV'YE-#,JD._:>245DC5V!8[1N M0AU$*$,&PW+2UN5_;4!_%$QI#8P\2ASA-_#XUG =*Z2%<0$K?)L@+*K-OW\ M1.E^@>?4GZ]E5!W'-A5FI FZ')[Y"<1]O*70[(%?XH#M4MRI7-A;.*W+;C$M?4:^<'C^"@'H=EQ-$ 5I3 8=ORW)" MX&%5D08G_ 'A#>LLQ6AG\&U71M)U)BJ6\-%CE:IR MWNC?AZ]RAL$.1\C^T' M'\'4FZ*^[T31-2Z3M<*^8YIH)>T.Q?$%=2 (ARTNN 8OY#Q9*<0;?&QI>^E. M-=)=1)"V,#9@>W(B47-[O*"H*.O\["=(-6?D1 NK8,K*I*BA_L1%8W MUOS+UCQ2UB[$Y[*LQUVIW5XS/Z%./IVJ?))F_N"ACO[RB[P)&UL4$L! A0#% @